Immunocore Selects Genedata to Scale Up Discovery of Novel TCR Therapeutics
September 5, 2024
Basel, Switzerland
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, announced today that Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, will use Genedata‘s central Scientific Data Management System (SDMS) to scale up discovery of novel TCR therapeutics.
The Genedata platform, purpose-built for automating R&D workflows for novel therapeutic modalities, offers both structured data management and assay analytics and makes data uniquely accessible for multimodal analysis and AI/ML applications.
“We are pleased that Immunocore has chosen Genedata to digitalize their data management as they work to develop and deliver transformative immunomodulating medicines,” said Othmar Pfannes, Ph.D., President of Genedata. “This underlines once more the quality of our software for innovative biotherapeutics.”
Immunocore will use Genedata’s SDMS to handle and make use of the increasing volume of complex R&D data across Immunocore’s modalities and workflows. The Genedata SDMS is built on Genedata Biologics® and Genedata Screener®, designed to maximize data value and streamline processes, leveraging insights to enhance protein engineering and reduce project timelines.
High-quality SDMS is crucial for data integrity, compliance, and accessibility, as well as enhanced decision-making, innovation, and competitive advantage. Genedata continues to demonstrate leadership in providing cutting-edge solutions for scientific data management and supporting biopharmaceutical companies in their quest to deliver life-changing therapies.
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
www.genedata.com
LinkedIn | X | YouTube
Contact
Genedata Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
We are pleased that Immunocore has chosen Genedata to digitalize their data management as they work to develop and deliver transformative immunomodulating medicines.
Othmar Pfannes, Ph.D.
President of Genedata